Why the study?
Does topical CGP 48933 reduce intraocular pressure in healthy volunteers and patients with early primary open-angle glaucoma?
Does topical CGP 48933 reduce intraocular pressure in healthy volunteers and patients with early primary open-angle glaucoma?
Topical application of the angiotensin-II-receptor blocker CGP 48933 is well tolerated but not effective for lowering intraocular pressure in humans.
Answers are grounded in this paper and cite their sources.
Topical CGP 48933 does not lower IOP in humans; challenges translation of rabbit model efficacy to clinical glaucoma therapy.
CGP 48933, a new angiotensin-II-receptor antagonist, has been shown to lower intraocular pressure (IOP) in two different rabbit glaucoma models in a dose-dependent manner after local application. As a further step a pilot study was performed in human eyes. The trial consisted of three parts. Parts 1 and 2 comprised a double-masked intraindividual trial between CGP 48933 and its vehicle (saline) in five healthy volunteers (Part 1) and five patients with early stages of primary open-angle glaucoma (Part 2), to assess local tolerance and the effect on IOP. Part 3 was a single-masked intraindividual trial between CGP 48933 and saline, to find the effective dose range of the new compound. Local tolerance was assessed as excellent in all subjects. No conjunctival hyperemia burning or itching occurred. There were no significant changes in IOP from baseline in drug or vehicle-treated eyes. In addition, there was no dose-dependent (200 micrograms to 1 mg) effect of CGP 48933 on IOP. Systemic blood pressure, heart rate and pupil size did not change during the observation period. Topical application of CGP 48933 in its present formulation is thus not suitable for lowering IOP in humans.
No takes yet. Share an insight, caveat, or question.
Kaiser et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: